Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Chinese University of Hong Kong
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histological confirmation of prostate adenocarcinoma
Low or intermediate risk prostate cancer patients (i.e. T1-T2c and PSA 20 and Gleason score \< 8) with the risk of pelvic node metastasis 15% as calculated by Roach's formula
ECOG performance score 0-1
Age ≥ 18
History/physical examination within 2 weeks prior to registration
Able to sign informed-consent
You may not be if
Patients with previous diagnosis of cancer other than prostate cancer and non-melanoma skin cancer.
Evidence of distant metastases
Regional lymph node involvement
Previous radical surgery (prostatectomy), cryosurgery, or HIFU for prostate cancer
Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
Previous hormonal therapy, such as LHRH agonists (e.g., goserelin, leuprolide) or LHRHantagonists (e.g., degarelix), anti-androgens (e.g., flutamide, bicalutamide), estrogens (e.g.DES), or surgical castration (orchiectomy)
Unstable angina and/or congestive heart failure requiring hospitalization, transmural myocardial infarction within the last 6 months, acute bacterial or fungal infection requiring intravenous antibiotics, chronic obstructive pulmonary disease exacerbation or other respiratory illness requiringhospitalization or precluding study therapy at the time of registration
Patients who have received prior chemotherapy.
Clareo Health | Stereotactic Body Radiotherapy vs Intensity-modulated Radiotherapy in Prostate Cancer
